Stock vs Stock Comparison

Boston Scientific Corporation vs Johnson & Johnson

BSX wins the Tale of the Tape 5–4.

BSX$47.68
JNJ$222.89

🏆 Tale of the Tape

54
BSXJNJ
14.4%Profitability (Net Margin)28.5%
20.2xValuation (P/E)26.1x
7.7%Efficiency (ROIC)18.3%
7/9Health (Piotroski F)4/9
3.9Safety (Altman Z)4.0
19.9%Growth (Rev YoY)6.0%
-1.50Risk (Sharpe 1Y)2.69
0.78xBalance Sheet (D/E)1.44x
3.37%FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.074
252-Day Correlation
0.024
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricBSXJNJ
Market Cap$71.8B$542.4B
P/E Ratio20.2x26.1x
Forward P/E12.9x17.7x
P/B2.78x6.68x
Dividend Yield2.38%
Beta0.620.26

Quantitative Metrics

MetricBSXJNJ
DCF Fair Value$75.06$134.24
DCF Upside+18.8%-43.6%
Piotroski F7/94/9
Altman Z3.883.97
Beneish M-2.52-2.27
FCF Yield3.37%3.25%
Net Debt/EBITDA1.8x0.5x
ROIC7.7%18.3%
WACC9.1%7.7%
ROIC – WACC-1.4pp10.5pp
Gross Margin69.0%67.9%
Net Margin14.4%28.5%
Rev Growth YoY19.9%6.0%
Sharpe (1Y)-1.502.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio64%

BSX Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

BSX found in:

IHI4.20%
XLV1.58%
XHE1.40%
VHT1.38%
MGK0.44%
SCHV0.38%
VUG0.26%
SPLG0.25%
IWD0.25%
IVV0.24%
ITOT0.21%
VONV0.21%
RSP0.20%
ESGV0.19%
SCHX0.18%
SCHB0.17%
SPYG0.16%
VFMV0.16%
ACWI0.15%
VOO0.14%
URTH0.13%
SPY0.13%
VONE0.13%
SPTM0.12%
VTI0.12%
QUS0.12%
SPYV0.10%
VT0.08%
IWF0.06%
VONG0.05%
ONEO0.02%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BSX vs JNJ: Head-to-Head Analysis

Boston Scientific Corporation (BSX) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, BSX leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BSX generates a return on invested capital (ROIC) of 7.7% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BSX and JNJ is 0.074, indicating low correlation, making them an effective diversification pair in a portfolio context.

BSX appears in 31 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BSX or JNJ?

Our quantitative analysis compares BSX and JNJ across nine fundamental dimensions. BSX wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BSX and JNJ correlated?

The 252-day correlation between BSX and JNJ is 0.074. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.